US EditionPublished • loading... • Updated
Psoriasis in Minors with Otezla (Amgen): Doubts in Efficacy and Weight Loss
Summary by redaccionmedica.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
The Therapeutic Positioning Report (IPT) that the Spanish Agency for Medicinal Products and Health Products (Aemps) recently published on apremilast (Otezla) in the paediatric population with moderate to severe plaque psoriasis leaves open several important doubts about its place in clinical practice. Issues that Medical Writing has transferred to Amgen, the titular laboratory of the drug, without having obtained a response despite the various r…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
